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ABSTRACT 
Purpose: Malignant pleural mesothelioma (MPM) is a disease with poor prognosis despite 
multimodal therapy but there is variation in survival between patients. Prognostic 
information is therefore potentially valuable in managing patients, particularly in the context 
of clinical trials where patients could be stratified according to risk. Therefore we have 
evaluated the prognostic ability of parameters derived from baseline 2-[18F]fluoro-2-deoxy-
D-glucose positron emission tomography / computed tomography (18F-FDG PET/CT). 
Methods: In order to determine the relationships between metabolic activity and prognosis 
we reviewed all 18F-FDG PET/CT scans used for pre-treatment staging of MPM patients in our 
institution between January 2005 and December 2011 (n = 60) and measured standardized 
uptake values (SUV) including mean, maximum and peak values, metabolic tumour volume 
(MTV) and total lesion glycolysis (TLG). Overall survival (OS) or time to last censor was 
recorded, as well as histological subtypes.  
Results: Median follow up was 12.7 months (1.9 - 60.9) and median OS was 14.1 months (1.9 
- 54.9). By univariable analysis histological subtype (p = 0.013), TLG (p = 0.024) and MTV (p = 
0.038) were significantly associated with OS and SUVmax was borderline (p = 0.051). On 
multivariable analysis histological subtype and TLG were associated with OS but at borderline 
statistical significance (p = 0.060 and 0.058, respectively). No statistically significant 
differences in any PET parameters were found between the epithelioid and non-epithelioid 
histological subtypes.  
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Conclusion: 18F-FDG PET/CT parameters that take into account functional volume (MTV, TLG) 
show significant associations with survival in patients with MPM before adjusting for 
histological subtype and are worthy of further evaluation to determine their ability to stratify 
patients in clinical trials. 
Key words: mesothelioma, 18F-FDG PET/CT, prognosis, standardised uptake value, total lesion 
glycolysis, metabolic tumour volume 
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INTRODUCTION 
Malignant pleural mesothelioma (MPM) is a primary tumour of the pleura that is causally 
linked to asbestos exposure in most cases. The disease arises in the parietal pleura, spreads 
contiguously to invade local structures, and can pass through the diaphragm into the 
abdominal cavity. The incidence of MPM is increasing, with the UK being currently in the midst 
of a ‘mesothelioma epidemic’ with the number of deaths having increased from 153 per 
annum in 1968 to 2046 in 2005 [1]. The disease is associated with poor prognosis and median 
survival from diagnosis is usually less than a year [2]. There is no known cure for MPM but 
treatment may involve a combination of radical surgery, chemotherapy and radiotherapy. To 
date, the outcomes of multi-modality therapy regimens have been disappointing with modest 
survival benefit [2,3]. Systemic chemotherapy plays a significant role in the management of 
this disease but is of limited efficacy with universally low objective tumour response rates in 
the clinic and a failure to impact highly on survival [3]. A therapeutic plateau has therefore 
been reached with conventional cytotoxic treatment requiring both the introduction of new 
biologically targeted drugs and, most importantly, a better understanding of the tumour 
biology which could lead to a better patient selection for targeted or radical therapies. 
2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) is the most commonly-used imaging tracer in 
combined positron emission tomography / computed tomography (PET/CT) [4] and has been 
widely utilized to stage and diagnose cancer [5]. Mesothelioma studies to date have shown 
that 18F-FDG PET/CT may differentiate benign from malignant pleural disease, detect 
mesothelioma recurrence and provide prognostic information in terms of staging, survival 
and mortality [6-10]. There is therefore potential to use the metabolic information from 18F-
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FDG PET/CT to better define the aggressiveness of MPM in individual patients such that 
treatment could be stratified in clinical trials. 
The study hypothesis was that parameters derived from 18F-FDG PET/CT, reflecting tumour 
metabolic activity, have prognostic significance in MPM. The aim of this retrospective study 
was to determine whether PET parameters reflecting metabolic activity (including maximum 
standardized uptake value (SUVmax), mean (SUVmean) and peak (SUVpeak) SUVs) and/or 
tumour volume (including metabolic tumour volume (MTV) and total lesion glycolysis (TLG)) 
[11] were associated with overall survival in a large cohort of patients scanned in our 
institution. 
 
MATERIALS AND METHODS 
Subjects 
All pre-treatment staging 18F-FDG PET/CT scans performed in patients with MPM at our 
institution between January 2006 and December 2011 were selected from the institutional 
PET database. Patients were included if they underwent whole body 18F-FDG PET/CT as part 
of their routine preoperative staging procedure before any therapy. Any patients with prior 
pleurodesis were excluded in view of the non-malignant uptake of 18F-FDG that results from 
this procedure. Demographic and clinicopathological data, including histological subtype, 
treatment details and overall survival (OS) were collected. Institutional approval was obtained 
to perform this retrospective analysis and requirement for informed consent was waived. 
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18F-FDG PET/CT and Analysis 
18F-FDG PET-CT scans were acquired using the same routine clinical oncology imaging protocol 
in the same institution on one of two scanners (Discovery VCT or DST, GE Healthcare, 
Waukesha, US). All 18F-FDG PET/CT scans were performed at 90 min (mean 89.7 min +/- 9.3) 
post injection of 350-400 MBq 18F-FDG after a 4 to 6 hour fast. Images were reconstructed 
using OSEM (2 iterations, 20 subsets) with a reconstructed slice thickness of 3.27mm and pixel 
size 5mm. The CT component of PET/CT scans was acquired at 140 kVp and 65 mAs without 
administration of oral or intravenous contrast agent and CT data was used for attenuation 
correction. All patients’ blood glucose levels were < 10 mmol/L at the time of 18F-FDG 
injection.  
18F-FDG PET data was analyzed on a dedicated workstation to measure SUVmax, SUVmean, 
SUVpeak, MTV (total volume of metabolically active tumour within a defined volume of 
interest) and TLG (SUVmean x MTV) [11] in primary MPM lesions using semi-automated 
software for volume of interest (VOI) placement and analysis (Hermes Gold 3, Stockholm) by 
a single operator. VOIs were initially selected using a predefined threshold of 40% of SUVmax 
[12] but were adjusted by the operator if non-tumoural areas of activity were incorrectly 
included within the VOI. Sixteen cases required a reduction in the threshold down to levels as 
far as 20% of SUVmax and 3 required an increase as far as 60%. Interobserver variability in 
performing these measurements with similar software has previously been reported as less 
than 5% [13]. 
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Statistical Analysis  
OS was defined as the time in months between the PET scan and the date of death. The time 
between PET scans and last censor was recorded in surviving patients. In each of the PET 
parameters, differences between epithelioid and non-epithelioid histological subtypes were 
tested by the Mann-Whitney U-test excluding the 9 cases with unknown histology. Subgroup 
analyses were not undertaken in other histological subtypes due to the small number of 
patients in each group.  
Cox regression was used to examine the effects of the PET parameters and other variables 
upon the survival outcomes and were performed in two stages. Initially the individual 
association of each variable with survival times was examined in a series of univariable 
analyses. Subsequently a multivariable analysis was performed to examine the joint effect of 
the variables retaining only variables significantly associated with survival. Some factors were 
omitted from the multivariable analyses where collinearity was found, with the clinically more 
relevant factors retained. Kaplan-Meier curves were generated for factors found to be 
significant predictors on univariable analysis. Differences in Kaplan-Meier survival curves 
were evaluated using a non-parametric log-rank test. A cut-point for the level of the PET 
parameters was calculated maximizing the sum of sensitivity and specificity from receiver 
operating characteristic (ROC) curves. P-values of less than 0.05 were considered statistically 
significant.  
RESULTS 
Sixty patients (mean age = 64.8 years, 51 males) were identified who had baseline 18F-FDG 
PET/CT scans before treatment (Table 1).  Thirty one patients had epithelioid subtype, with 
the remaining patients showing a mixed (n = 13), sarcomatoid (n = 5) or desmoplastic (n = 2) 
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subtype. In 9 patients it was not possible to confirm histological results. TNM and overall stage 
were assessed by a combination of surgery, when performed, diagnostic CT scans and 18FDG 
PET/CT (Table 1). Thirty-two patients underwent radical therapy including radical 
pleurectomy / decortication and hyperthermic intrapleural lavage with povidone-iodine, 
adjuvant chemotherapy (platinum and pemetrexed combination chemotherapy) and 
prophylactic chest wall radiotherapy (21Gy in 3 fractions using orthovoltage radiation) [14]. 
Twenty-eight patients underwent palliative therapy including a videothoracoscopic 
procedure for talc pleurodesis or insertion of a pleurX catheter, usually followed by 
prophylactic radiotherapy on port sites (as above) and chemotherapy (as above). 
Whilst 18F-FDG PET/CT scans were performed for clinical staging in this cohort, the volume 
and intensity of active disease as measured by the PET parameters was not used for decisions 
between palliative or curative management options. In 4 cases it was not possible to measure 
SUVpeak as the required volume of tumour was too low or of a shape that could not 
accommodate a 1 cm3 sphere and additionally in 2 of these cases SUVmean could not be 
calculated as it was not possible to confidently define the tumour edge for ROI definition. 
No statistically significant differences in PET parameters were found between the epithelioid 
and non-epithelioid histological subtypes (Table 2). 
Median follow up was for 12.7 months (1.9 - 60.9) and median OS was 14.1 months (1.9 - 
54.9). Results of univariable and multivariable Cox regression analysis, used to examine the 
effects of PET parameters and other variables on overall survival outcomes, are shown in table 
3. When examined individually, histological group, TLG and MTV were significantly associated 
with survival times (p = 0.013, 0.024 and 0.038, respectively). The other variables including 
age, sex, stage, SUVmean and SUVpeak were not significantly associated with patient survival 
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although SUVmax was borderline (p = 0.051). Epithelioid patients had a lower risk of death, 
with the risk of death at any time less than half that of non-epithelioid patients. The second 
stage in the analyses examined the joint association between the factors and survival times 
in a multivariable analysis. Before this analysis was performed variance inflation factors were 
calculated to assess collinearity between variables. These suggested that MTV and TLG were 
collinear and only TLG was subsequently included in the multivariable analysis. Additionally 
SUV max and SUVpeak were also found to be collinear and as SUVpeak was not significant in 
the univariable analysis it was omitted from the multivariable analyses. A backwards selection 
procedure was used to retain only variables showing some association with survival (histology 
and TLG). The final model is summarised in table 3. Of the variables considered for the 
multivariable analyses, there was some evidence that both histological group and TLG were 
associated with patient survival, although the results for both variables were only of 
borderline statistical significance (p = 0.060 and 0.058, respectively).  As in the univariable 
analyses, patients in the epithelioid group had a lower risk of death, whilst the risk was higher 
in patients with higher TLG values. By Kaplan-Meier analysis of the factors that were 
significant in univariable analysis (histology, SUVmax, MTV and TLG), OS was lower in patients 
with non-epithelioid histology (median 8.3 vs 22.0 months, p = 0.01), high SUVmax > 6.3 
(median 11.1 vs 46.6 months, p = 0.004), MTV > 755 ml (6.4 vs 14.4 months, p = 0.001) and 
TLG > 2914 ml (6.4 vs 18.1 months, p = 0.0002) (Fig. 1).  
 
DISCUSSION 
In a large series of patients with MPM we have shown that parameters derived from pre-
treatment 18F-FDG PET/CT scans that relate to the volume of metabolically active disease 
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(MTV) and both the volume and activity of disease (TLG = MTV x SUVmean), are associated 
with OS on univariable analysis whilst SUVmax was of borderline significance (p = 0.051). 
Relationships are stronger between OS and PET parameters that take into account the volume 
of metabolically active tumour (MTV) or both tumour activity and volume (TLG),  than those 
that measure uptake only (SUVmax, SUVmean and SUVpeak). On multivariable analysis 
histology and TLG showed an association with OS, although both were of borderline statistical 
significance (p = 0.060 and 0.058, respectively). On Kaplan-Meier analysis of the factors 
showing significance in the univariable analysis, a difference in survival was seen between 
subjects with epithelioid and non-epithelioid histology, low and high values of SUVmax, MTV 
and TLG suggesting these variables could be further evaluated for stratifying patients. A 
relationship between 18F-FDG uptake and prognosis is not unexpected in MPM as uptake of 
18F-FDG has previously been shown to be associated with Glut-1 and hexokinase 1 expression 
as well as factors related to hypoxia, angiogenesis, proliferation, cell cycle regulation and the 
mTOR signaling pathway; factors that are known to be associated with more aggressive 
behavior [15]. 
Although some previous studies have shown relationships between survival and SUVs in 
patients with MPM [6,7,16], this has not been confirmed in all [17,18]. There has been more 
recent interest in using prognostic PET parameters that also take metabolically active tumour 
volume into account, such as MTV and TLG (also referred to as total glycolytic volume or TGV) 
[18]. A longitudinal change in TLG (TGV) after chemotherapy has also been shown to predict 
response after one cycle and is associated with survival [19]. 
The use of parameters that take both tumour activity and tumour volume into account in 
determining prognosis is intuitive, as both tumour activity and total tumour burden are 
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related to outcome in many tumours. TLG has been used in previous analyses of non-
mesothelioma tumours as a global measure of all sites of tumour for response assessment 
[20,21] and it has been recommended that TLG data is acquired in trials for secondary analysis 
[11]. In MPM, changes in SUVmax and TLG have been reported to be inferior to morphological 
response assessment to chemotherapy [22] and in another study MTV and TLG treatment 
response changes were predictive of survival [23]. A further study found MTV and TLG to be 
predictive for recurrence after surgery or progression following chemotherapy [24].  
Different histological subtypes have been reported as being related to OS and in particular 
sarcomatoid histology is associated with a poor prognosis [18]. On 18F-FDG PET analysis, an 
association has been reported between TGV and OS in a univariable analysis of 89 patients 
but only in non-sarcomatoid (n = 82) patients on multivariable analysis [18]. However, 
sarcomatoid histology is relatively rare and it was suggested that these patients should be 
considered as a different group for stratification. Variation in SUVmax between subtypes of 
epithelioid tumours has been described with more pleomorphic subtypes being over 
represented in a group with high SUVmax [25]. A positive correlation with mitotic count was 
also reported.  
Patients with MPM are frequently treated with pleurodesis. This procedure causes an 
inflammatory reaction in the pleura that can be associated with intense 18F-FDG activity [26] 
and this is a potential limitation for analysing MPM tumour activity on PET scans. Despite 
this, MTV (TGV) has been reported to retain predictive power for survival in a subgroup 
analysis of patients with previous talc pleurodesis [18]. In our study, only patients without 
any form of prior treatment were included to exclude any confounding effects on 18F-FDG 
accumulation and so we were unable to assess the effects of previous pleurodesis in our 
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cohort. This study is also limited by its retrospective nature and the patient group included 
those selected for radical and palliative therapy options. Whilst therapeutic strategies for 
mesothelioma may have changed during the period that 18F-FDG PET/CT scans were 
included in this study, it is recognised that there has been little impact in prognosis of MPM 
worldwide [2,3] and it is therefore unlikely that significant changes in prognosis and OS will 
have evolved over the study period to bias our results. Whilst there were sufficient patients 
with epithelioid histology for subgroup analysis, other histological subtypes had too few 
patients for meaningful comparison and histological data was missing in 9 cases. 
 
CONCLUSION 
18F-FDG PET/CT parameters that take into account functional volume (MTV, TLG) show 
significant associations with survival in patients with MPM before adjusting for histological 
subtype. Prospective evaluation is required but PET parameters show promise as possible 
methods to stratify patients in clinical trials. 
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TABLES 
Table 1. Patient demographic and clinical characteristics.  
Patient Characteristics Number (%) 
Age mean and [range] 64.8 years (45-79) 
Gender 
Male 
Female 
 
51 (85%) 
9 (15%) 
Histological subtype 
Epithelioid 
Sarcomatoid 
Mixed 
Desmoplastic 
Unknown 
 
31 (52%) 
5 (8%) 
13 (22%) 
2 (3%) 
9 (15%) 
Overall tumour stage (AJCC) 
1 
2 
3 
 
4 
 
 
9 (15%) [T1N0M0, n=9] 
13 (22%) [T2N0M0, n=13] 
27 (45%) [T2N1M0, n=3, T2N2M0, n=8, T3N0M0, n=12, 
T3N1M0, n=2, T3N2M0, n=2] 
11 (7%) [T2N3M0, n=2, T4N0M0, n=3, T4N2M0, n=3, 
T4N2M1, n=1, T4N3M1, n=2] 
Therapy 
Radical 
Palliative 
 
32 (53%) 
28 (47%) 
 
(AJCC - American Joint Committee on Cancer 7th edition [27]) 
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Table 2. PET parameters in histological subtypes 
 
Parameter Mean epithelioid  Mean non-
epithelioid 
S.D. P value 
SUVmax 11.5  11.6 6.6 (4.9) 0.69 
SUVmean 4.5  4.5 1.9 (1.7) 0.95 
SUVpeak 10.1 9.4 5.3 (3.9) 0.32 
TLG (ml) 2392 2704 3039 (3061) 0.97 
MTV (ml) 436  551 424 (582) 0.90 
 
S.D. standard deviation. Non-epithelioid S.D. in parentheses.  
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Table 3: Univariable and multivariable analyses 
 
Variable Category Univariable analysis Multivariable analysis 
Hazard Ratio  
(95% CI) 
P-value Hazard Ratio  
(95% CI) 
P-
value 
      
Age (**) - 0.96 (0.64, 1.44) 0.84   
      
Sex Male    1 0.22   
 Female 0.56 (0.22, 1.41)    
      
Histological 
group 
Non-Epithelioid    1 0.013    1 0.060 
 Epithelioid 0.43 (0.22, 0.84)  0.53 (0.28, 1.03)  
      
Stage 1    1 0.34   
 2 0.50 (0.18, 1.39)    
 3 0.98 (0.43, 2.23)    
 4 1.21 (0.46, 3.14)    
      
SUVmax (*) - 1.26 (1.00, 1.58) 0.051   
SUVmean - 1.11 (0.96, 1.28) 0.15   
SUVpeak  
(*) 
- 1.26 (0.93, 1.69) 0.14   
TLG (†) - 1.25 (1.03, 1.52) 0.024 1.25 (0.99, 1.51) 0.058 
MTV (†) - 1.27 (1.01, 1.58) 0.038   
20 
 
      
 
The effects of variables on overall survival in univariable and multivariable analyses. 
(*)   Hazard ratios given for a 5-unit increase in explanatory variable 
(**) Hazard ratios given for a 5-unit increase in explanatory variable 
(†)   Variable analysed on log scale 
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FIGURE LEGENDS 
FIGURE 1. Kaplan-Meier plots showing differences in overall survival (OS) between patients 
with i) epithelioid and non-epithelioid histology, ii) SUVmax, iii) MTV and iv) TLG. 
 
 
 
 
 
 
 
